Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China flag China · Delayed Price · Currency is CNY
44.65
-1.88 (-4.04%)
Sep 11, 2026, 3:00 PM CST

SHA:688513 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3341,3291,3481,1161,1701,023
Other Revenue
1.632.31.841.420.630.07
1,3361,3311,3501,1171,1711,023
Revenue Growth
0.09%-1.36%20.82%-4.56%14.43%10.96%
Cost of Revenue
332.21336.21345.23226.94199.11146.32
Gross Profit
1,004995.181,005890.18971.4876.62
Selling, General & Admin
516.51517.78552.93483.43564.44528.06
Research & Development
285.04262.74262.77237.45229.99199.59
Other Operating Expenses
45.6415.9417.3717.4618.1515.75
Operating Expenses
845.77796.24836.11737.98814741.14
Operating Income
157.86198.94168.42152.2157.4135.47
Interest Expense
-2.61-2.51-3.68-3.42-2.61-0.36
Interest & Investment Income
47.852.1127.3825.6120.6932.83
Currency Exchange Gain (Loss)
-1.61-0.420.1600.030.02
Other Non Operating Income (Expenses)
-0.16-0.10.28-0.1-0.11-0.19
EBT Excluding Unusual Items
201.29248.01192.56174.29175.41167.77
Gain (Loss) on Sale of Investments
21.0617.1314.9214.5719.9913.69
Gain (Loss) on Sale of Assets
-0.33-0.18-0.110.030.19-0.1
Other Unusual Items
62.1434.6945.2252.7666.465.56
Pretax Income
284.15299.65252.59241.64261.99246.92
Income Tax Expense
35.0526.0814.3515.0715.4714.49
Earnings From Continuing Operations
249.11273.57238.23226.57246.52232.43
Minority Interest in Earnings
28.1310.49----
Net Income
277.24284.06238.23226.57246.52232.43
Net Income to Common
277.24284.06238.23226.57246.52232.43
Net Income Growth
21.43%19.23%5.15%-8.09%6.06%30.46%
Shares Outstanding (Basic)
173174175177177176
Shares Outstanding (Diluted)
173174175177177176
Shares Change
-1.34%-0.52%-1.04%0.14%0.37%19.70%
EPS (Basic)
1.601.631.361.281.391.32
EPS (Diluted)
1.601.631.361.281.391.32
EPS Growth
23.08%19.85%6.25%-8.22%5.68%8.98%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
181.29178.66145.8299.99-187.38-122.59
Free Cash Flow Per Share
1.051.020.830.56-1.06-0.70
Dividend Per Share
0.4900.4900.4300.3950.3810.531
Dividend Growth
13.95%13.95%8.97%3.57%-28.19%159.97%
Gross Margin
75.13%74.75%74.42%79.68%82.99%85.70%
Operating Margin
11.82%14.94%12.48%13.62%13.45%13.24%
Profit Margin
20.75%21.34%17.65%20.28%21.06%22.72%
Free Cash Flow Margin
13.57%13.42%10.80%8.95%-16.01%-11.98%
EBITDA
262.93289.92251.25225.43215.75168.08
EBITDA Margin
19.68%21.78%18.62%20.18%18.43%16.43%
D&A For EBITDA
105.0790.9982.8473.2358.3532.6
EBIT
157.86198.94168.42152.2157.4135.47
EBIT Margin
11.82%14.94%12.48%13.62%13.45%13.24%
Effective Tax Rate
12.33%8.70%5.68%6.24%5.90%5.87%
Revenue as Reported
1,3361,3311,3501,1171,1711,023
Advertising Expenses
----403393.56